China’s streamlined system for biologics approvals has enabled Shanghai Henlius Biotech to bring biosimilars to market faster and potentially at a lower cost, Ping Cao, vice president of Business Development, explains.
The Center for Biosimilars® spoke recently with Ping Cao, vice president of Business Development for Shanghai Henlius Biotech about the company’s business activities and conditions for biosimilar developers in the Chinese market. Established in 2010, Henlius is notable for having brought the first biosimilar to the Chinese market, a rituximab product. Henlius has a robust pipeline of products and ambitions to partner with companies abroad for global sales development.
In the interview, Cao talks about recent changes in Chinese guidance for biosimilar development and how these have quickened the pace of approvals and improved conditions for companies entering these markets. For example, previously it may have taken 3 years from the time of an investigational new drug (IND) application to gain regulatory approval to commence a clinical trial. That timeline has been shortened to 60 days under the new regulatory standard in China, which has established timing guarantees that allow companies to proceed if they do not receive a response to IND applications within 2 months.
In this sense, the Chinese government has been an active partner with the biologics industry and has extended opportunities for talks with the business sector on how to further improve the regulatory system. This bodes well for the future of biosimilars development and marketing, Cao explains.
Cao also provides a comparison of the regulatory environments in the United States and China and discusses the competitive dynamics of producing biosimilars and gaining market share as the number of competitors and competing products continue to increase. For Henlius, the costs of producing a biosimilar can range up to $100 million, and to meet regulatory standards in the United States and European Union, the costs could go higher than that, Cao explains. Meanwhile, producers need to keep their biosimilar prices competitive with what others are charging. Therefore, these 2 dynamics—cost of production and pricing—may move on opposing trendlines.
Cao also talks about the promising market in China for the company’s adalimumab biosimilar (referencing Humira), which was approved by China’s National Medical Products Administration in late 2020 for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis. Within China, Henlius has an extensive network of hospital partners and a large sales team, with which the company believes it can reach a population exceeding 6 million patients in China.
For more reading about Henlius’ biosimilars portfolio, pipeline, and global development ambitions, click here.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.